Hepatic arterial infusion in hepatocellular carcinoma: a single center experience.
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33150533" target="_blank" >RIV/61989592:15110/15:33150533 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11150/15:10319149 RIV/00179906:_____/15:10319149
Výsledek na webu
<a href="http://dx.doi.org/10.5507/bp.2014.054" target="_blank" >http://dx.doi.org/10.5507/bp.2014.054</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2014.054" target="_blank" >10.5507/bp.2014.054</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Hepatic arterial infusion in hepatocellular carcinoma: a single center experience.
Popis výsledku v původním jazyce
AIM: The aim of the present study was to evaluate a single center experience with hepatic arterial infusion (HAI) in patients with hepatocellular carcinoma. METHODS: A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007. RESULTS: Most patients were treated with an HAI of doxorubicin and cisplatin combined with 5-fluorouracil and folinic acid. The response was not evaluable in the majority of patients, predominantly because of associated surgical procedure orbecause only one cycle of HAI was administered. The median progression-free survival was 7.7 months. The median survival of all patients was 12.2 months (5-year survival 5%). Serious adverse events were observed in 5 patients, and one patient died of liver failure in association with the administration of HAI. CONCLUSION: The data show the limited efficacy of HAI in patients with hepatocellular carcinoma.
Název v anglickém jazyce
Hepatic arterial infusion in hepatocellular carcinoma: a single center experience.
Popis výsledku anglicky
AIM: The aim of the present study was to evaluate a single center experience with hepatic arterial infusion (HAI) in patients with hepatocellular carcinoma. METHODS: A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007. RESULTS: Most patients were treated with an HAI of doxorubicin and cisplatin combined with 5-fluorouracil and folinic acid. The response was not evaluable in the majority of patients, predominantly because of associated surgical procedure orbecause only one cycle of HAI was administered. The median progression-free survival was 7.7 months. The median survival of all patients was 12.2 months (5-year survival 5%). Serious adverse events were observed in 5 patients, and one patient died of liver failure in association with the administration of HAI. CONCLUSION: The data show the limited efficacy of HAI in patients with hepatocellular carcinoma.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Biomedical Papers-Olomouc
ISSN
1213-8118
e-ISSN
—
Svazek periodika
159
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
CZ - Česká republika
Počet stran výsledku
6
Strana od-do
139-144
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—